Angiogenesis, the formation of new blood vessels, plays an important role in tumor growth and metastasis. Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key regulator of this process and a crucial target for anti-angiogenic cancer therapies. In this work, a series of pyrazole–pyrazoline derivatives were designed by incorporating various heterocyclic moieties, such as thiazole, benzothiazole, pyridine, furan, thiophene, and pyrrole, to improve VEGFR-2 inhibition. Using an in silico approach, molecular docking studies with AutoDock Vina revealed strong binding interactions, particularly hydrophobic and hydrogen bonding, with amino acid residues of the VEGFR-2 protein. The compounds were tested for pharmacokinetic properties and drug-likeness using SwissADME, and their absorption, distribution, metabolism, excretion, and toxicity profiles were predicted through the pkCSM tool. Among the tested compounds, C-64 emerged as the most promising lead candidate, showing optimum binding affinity, compliance with Lipinski’s and Veber’s rules, and no predicted hepatotoxicity, cardiotoxicity, or mutagenicity. Moreover, C-64 displayed a high LD50 value, suggesting low toxicity, and the lowest total clearance, indicating prolonged retention. It also aligned well with key physicochemical parameters in the bioavailability radar and was positioned in the white region of the BOILED-Egg model, suggesting efficient gastrointestinal absorption. These findings position C-64 as a promising candidate for further optimization and preclinical development in cancer therapy.
Wanode DM, Bhendarkar KP, Khedekar PB. Discovery of pyrazole–pyrazoline derivatives as VEGFR-2 kinase inhibitors: In silico approach. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.256031
1. Reddy VG, Reddy TS, Jadala C, Reddy MS, Sultana F, Akunuri R, et al. Pyrazolo-benzothiazole hybrids: synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model. Eur J Med Chem. 2019;15:182. doi: https://doi.org/10.1016/j.ejmech.2019.111609
2. Ahmed MF, Santali EY, El-Haggar R. Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. J Enzyme Inhib Med Chem. 2021;36(1):307–18. doi: https://doi.org/10.1080/14756366.2020.1861606
3. Ravula P, Vamaraju HB, Paturi M, Sharath Chandra JNGN. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors. Arch Pharm (Weinheim). 2018;351(1):e1700234. doi: https://doi.org/10.1002/ardp.201700234
4. Ding Y, Liu K, Zhao X, Lv Y, Yu R, Kang C. Design, synthesis, and antitumor activity of novel benzoheterocycle derivatives as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. J Chem Res. 2020;44(5–6):286–94. doi: https://doi.org/10.1177/1747519819899067
5. Mohamed TK, Batran RZ, Elseginy SA, Ali MM, Mahmoud AE. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorg Chem. 2019;85:253–73. doi: https://doi.org/10.1016/j.bioorg.2018.12.040
6. El-Helby AGA, Sakr H, Eissa IH, Al-Karmalawy AA, El-Adl K. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Arch Pharm (Weinheim). 2019;352(12):e1900178. doi: https://doi.org/10.1002/ardp.201900178
7. Wang XR, Wang S, Li WB, Xu KY, Qiao XP, Jing XL, et al. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors. Eur J Med Chem. 2021;213:113192. doi: https://doi.org/10.1016/j.ejmech.2021.113192
8. Thaher BA, Arnsmann M, Totzke F, Ehlert JE, Kubbutat MHG, Schächtele C, et al. Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. J Med Chem. 2012;55(2):961–5. doi: http://dx.doi.org/10.1021/jm201391u
9. Adams CM, Anderson K, Artman G, Bizec JC, Cepeda R, Elliott J, et al. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino) methyl) pyrimidin-4-yl)oxy)-1Hindole-1-carboxamide (Acrizanib), a VEGFR-2 inhibitor specifically designed for topical ocular delivery, as a therapy for neovascular agerelated macular degeneration. J Med Chem. 2018;61(4):1622–35. doi: https://doi.org/10.1021/acs.jmedchem.7b01731
10. Ruzi Z, Bozorov K, Nie L, Zhao J, Aisa HA. Novel pyrazolo[3,4-d] pyrimidines as potential anticancer agents: synthesis, VEGFR-2 inhibition, and mechanisms of action. Biomed Pharmacother. 2022;156:113948. doi: https://doi.org/10.1016/j.biopha.2022.113948
11. Alam R, Alam A, Panda AK, Rahisuddin. Design, synthesis and cytotoxicity evaluation of pyrazolyl pyrazoline and pyrazolyl aminopyrimidine derivatives as potential anticancer agents. Med Chem Res. 2018;27(2):560–70. doi: http://dx.doi.org/10.1515/hc-2016-0042
12. Srinivasa Reddy T, Kulhari H, Ganga Reddy V, Subba Rao AV, Bansal V, Kamal A, et al. Synthesis and biological evaluation of pyrazolotriazole hybrids as cytotoxic and apoptosis inducing agents. Org Biomol Chem. 2015;13(40):10136–49. doi: https://doi.org/10.1039/C9OB90120E
13. Alam R, Wahi D, Singh R, Sinha D, Tandon V, Grover A, et al. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents. Bioorg Chem. 2016;69:77–90. doi: https://doi.org/10.1016/j.bioorg.2016.10.001
14. Dawood DH, Nossier ES, Ali MM, Mahmoud AE. Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorg Chem. 2020;101:103916. doi: https://doi.org/10.1016/j.bioorg.2020.103916
15. Ashour GRS, Qarah AF, Alrefaei AF, Alalawy AI, Alsoliemy A, Alqahtani AM, et al. Synthesis, modeling, and biological studies of new thiazole-pyrazole analogues as anticancer agents. J Saudi Chem Soc. 2023;27(4):101669. doi: https://doi.org/10.1016/j.jscs.2023.101669
16. Upadhyay N, Tilekar K, Safuan S, Kumar AP, Schweipert M, Meyer-Almes FJ, et al. Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks. RSC Med Chem. 2021;12(9):1540–54. doi: https://doi.org/10.1039/D1MD00125F
17. Wang M, Xu S, Lei H, Wang C, Xiao Z, Jia S, et al. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold. Bioorg Med Chem. 2017;25(20):5754–63. doi: https://doi.org/10.1016/j.bmc.2017.09.003
18. Wickens P, Kluender H, Dixon J, Brennan C, Achebe F, Bacchiocchi A, et al. SAR of a novel “Anthranilamide Like” series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. Bioorg Med Chem Lett. 2007;17(15):4378–81. doi: http://dx.doi.org/10.1016/j.bmcl.2007.02.075
19. Eldebss TMA, Gomha SM, Abdulla MM, Arafa RK. Novel pyrrole derivatives as selective CHK1 inhibitors: design, regioselective synthesis and molecular modeling. Med Chem Comm. 2015;6(5):852–9. doi: https://doi.org/10.1039/C4MD00560K
20. Underiner TL, Ruggeri B, Aimone L, Albom M, Angeles T, Chang H, et al. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs. Bioorg Med Chem Lett. 2008;18:2368–2372. doi: https://doi.org/10.1016/j.bmcl.2008.02.069
Year
Month